{"id":"W3194210289","doi":"10.1136/jitc-2021-003188","title":"Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EUSA Pharma; Ipsen; Pharmacyclics; Eisai; Incyte; Genentech; Les Laboratories Pierre Fabre; AstraZeneca; Pfizer; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Adjuvant; Ipilimumab; Adverse effect; Oncology; Internal medicine; Proportional hazards model; Melanoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002249032,0.0001669967,0.0006471588,0.00009820655,0.0001353313,0.00002447518,0.0001038662,0.0001132124,0.0003496663],"category_scores_gemma":[0.0002041435,0.0001248415,0.0002851852,0.0001651176,0.00006514484,0.0001417383,0.00001110674,0.000143458,5.736075e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005698089,"about_ca_system_score_gemma":0.001093398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000174257,"about_ca_topic_score_gemma":0.0004698581,"domain_scores_codex":[0.9980021,0.00009847122,0.0006667508,0.0001834904,0.0008275417,0.0002217212],"domain_scores_gemma":[0.9966903,0.0002819026,0.0009227663,0.0002529088,0.001804464,0.00004764901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06903238,0.0005327454,0.1936789,0.0005705777,0.007442035,0.000002895819,0.002238605,0.0001045129,0.1136142,0.0002133948,0.00344473,0.609125],"study_design_scores_gemma":[0.1716409,0.005176552,0.6213244,0.001616863,0.002152529,0.00007115531,0.002316711,0.001252809,0.09345902,0.001198719,0.09915072,0.0006396712],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560984,0.0358874,0.001886552,0.002906984,0.001292864,0.001229171,0.0004200065,0.000009999052,0.0002686153],"genre_scores_gemma":[0.9558552,0.02801216,0.005034252,0.000552922,0.0004739472,0.0002930885,0.0000836348,0.0001074173,0.009587362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6084853,"threshold_uncertainty_score":0.5090888,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03369585980913195,"score_gpt":0.3512298565537758,"score_spread":0.3175339967446438,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}